About Corcept Therapeutics (CORT)

Corcept Therapeutics Inc (CORT) is a pharmaceutical company that specializes in the development and commercialization of drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders. The company focuses on discovering and developing small molecule drugs that selectively modulate the effects of cortisol. Corcept's lead product, Korlym, is an oral medication that is approved for the treatment of hyperglycemia in patients with endogenous Cushing's syndrome. The company is also conducting clinical trials to evaluate the use of Korlym in the treatment of various types of cancer, including ovarian, lung, and pancreatic cancer.

In terms of stock performance, Corcept Therapeutics Inc has had a relatively stable history. Over the past five years, the stock price has fluctuated between a low of $7.50 and a high of $25.00. Currently, the stock is trading around $15.00. The market capitalization of Corcept Therapeutics Inc is approximately $1.5 billion. The company has a PEG ratio of 1.42, indicating that the stock may be slightly overvalued compared to its industry peers. However, it is important to note that the biopharmaceutical industry as a whole tends to have higher valuations due to the high-risk nature of drug development. Corcept Therapeutics Inc is also trading below its 52-week high of $24.00, suggesting that there may be potential for price appreciation in the future.